Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01556503 · ClinicalTrials.gov registry record
Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis
A clinical trial of Melanoma, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- 24
- Enrollment target
- 1
- Study location
NCT01556503 is a study of Melanoma that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 24 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01556503, a study of Melanoma, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to show how well a new device, confocal microscope, works to detect malignant melanoma, a type of skin cancer.
Conditions Studied
Interventions
- DEVICE VivaScope System
Study Locations (1)
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01556503
The ClinicalTrials.gov registry entry for NCT01556503 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (97% lower). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which VivaScope System is the first listed.
NCT01556503 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT01556503 about?
NCT01556503 is a clinical study titled "Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis". The purpose of this study is to show how well a new device, confocal microscope, works to detect malignant melanoma, a type of skin cancer.
What is the current status of trial NCT01556503?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2011-04. Estimated completion is 2013-11.
What conditions does trial NCT01556503 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT01556503?
The interventions under investigation include: VivaScope System (DEVICE).
Who is sponsoring clinical trial NCT01556503?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01556503 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.